Menu Search
Equities

Boiron SA

BON:BER

Boiron SA

Actions
  • Price (EUR)31.35
  • Today's Change0.10 / 0.32%
  • Shares traded--
  • 1 Year change-25.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

  • Revenue in EUR (TTM)481.71m
  • Net income in EUR23.69m
  • Incorporated1967
  • Employees2.79k
  • Location
    Boiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
  • Phone+33 478456100
  • Fax+33 478456291
  • Websitehttps://www.boiron.fr/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.